Cancer Pharmacokinetics and Pharmacodynamics Facility

癌症药代动力学和药效学设施

• 批准号: 10254101
• 负责人: Jan Hendrik Beumer
• 金额: $ 19.87万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-09-10 至 2025-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10254101
• 关键词: Adopted; Advisory Committees; Antineoplastic Agents; Award; Biological Assay; Budgets; Cancer Center; Cancer Center Support Grant; Capital; Cells; Clinical; Clinical Pharmacology; Clinical Trials; Clinical Trials Network; Communities; DNA Damage; DNA Markers; Data; Data Analyses; Development; Drug Kinetics; Ensure; Equipment; Exposure to; Freezing; Funding; High Pressure Liquid Chromatography; Human Resources; Hybrids; Injections; Investigation; Ions; Joints; Label; Lead; Liquid substance; Malignant Neoplasms; Measures; Medicine; Methodology; Methods; NCI Center for Cancer Research; Nitrogen; Outcome; Peer Review Grants; Pharmaceutical Preparations; Pharmacodynamics; Pharmacologic Substance; Pharmacology; Phase I Clinical Trials; Phase II Clinical Trials; Philosophy; Population; Power Sources; Procedures; Process; Publications; Quality Control; Reader; Reagent; Research; Research Design; Research Personnel; Resource Sharing; Role; Sampling; Science; Scientist; Scintillation Counter; Services; Site; Specialist; Therapeutic Studies; Training; Translational Research; Validation; Water; absorption; drug development; early phase clinical trial; experience; instrumentation; meetings; member; mid-career faculty; novel; novel anticancer drug; pharmacodynamic biomarker; pharmacokinetics and pharmacodynamics; pre-clinical; professor; programs; sample collection; skills; small molecule

Abstract: Cancer Pharmacokinetics and Pharmacodynamics Facility (CPPF) The Hillman Cancer Center (HCC) Cancer Pharmacokinetics and Pharmacodynamics Facility (CPPF) is an important shared resource that supports science conducted by the HCC research programs and has a major impact on cancer drug development on a national level by providing state-of-the-art and comprehensive quantitative and qualitative bioanalytical support for preclinical and clinical cancer therapeutic studies. The activities of CPPF have earned national recognition for its exceptional service in developing and delivering PK and PD analyses of investigational agents. CPPF: (1) provides extensive pharmacology expertise to investigators by assisting in PK and PD study design and sample collection; (2) develops and provides quality-assured/quality-controlled quantitative and qualitative assay capabilities for rapid and efficient PK and PD bioanalyses; and (3) integrates PK/PD data through sophisticated data analyses. CPPF is located in two contiguous lab spaces with a shared office pod in the HCC Research Pavilion. Major equipment includes 3 Waters QuattroMicro LC-MS/MS, 2 SCIEX4000 LC-MS/MS (1 hybrid linear ion-trap), 2 HPLC-UV/FL/DAD, 1 HPLC-UV/RAD, 1 atomic absorption spectrometer, a LICOR Odyssey infra-red scanner, a Tecan Infinite Microplate Reader, and a Nexcelom Cellometer K2 Cell counter. Ancillary equipment includes -20 °C and -80 °C freezers, a nitrogen generator, and an uninterrupted power supply, as well as access to shared instrumentations including a liquid scintillation counter. CPPF is directed by Drs. Jan Beumer, Professor of Pharmaceutical Sciences and Medicine, and John Schmitz, Associate Professor of Medicine, and is overseen by an HCC Advisory Committee made up of HCC members. Dr. Beumer leads and Dr. Schmitz actively participates in the weekly Merrill Egorin Translational Research meeting, where HCC early drug development projects are discussed by an inter- disciplinary group of basic, translational, and clinical scientists, thereby ensuring appropriate consideration of CPPF’s role in these projects. During this funding period, CPPF analyzed samples for a total of 36 unique investigators and provided support for all 7 HCC research programs. During this funding period, CPPF developed 37 new assays, an average of 22 assays were used per year, and more than 30,000 samples were analyzed (excluding calibrators, quality controls or assay validation samples). CPPF supported 30 peer-reviewed grants and 70 publications, 30 of which were focused on clinical trials, and 19 of which focused on development of novel assay methodologies.

摘要：肿瘤药代动力学和药效学实验装置 希尔曼癌症中心癌症药代动力学和药效学设施(CPPF)是一家 重要的共享资源，支持由肝细胞癌研究计划进行的科学，并具有重要的 通过提供最先进和全面的技术，在国家一级影响抗癌药物的开发 为临床前和临床癌症治疗研究提供定量和定性的生物分析支持。这个 CPPF的活动因其在开发和交付方面的出色服务而获得全国认可 调查试剂的PK和Pd分析。 CPPF：(1)通过协助PK和PD研究设计，为研究人员提供广泛的药理学专业知识 和样本采集；(2)开发和提供有质量保证/质量控制的数量和质量 快速高效的PK和PD生物分析的分析能力；以及(3)通过以下方式集成PK/PD数据 复杂的数据分析。 CPPF位于两个毗连的实验室空间，在HCC研究展馆共用一个办公吊舱。主修 设备包括3个Waters QuattroMicro LC-MS/MS，2个SCIEX4000 LC-MS/MS(1个混合线性离子陷阱)，2个 高效液相-UV/FL/DAD，1台高效液相-UV/RAD，1台原子吸收光谱仪，一台LICOR奥德赛红外扫描仪， 一台Tecan无限微板阅读器和一台Nexelom Celleter K2细胞计数器。辅助设备包括 -20摄氏度和-80摄氏度冰柜、氮气发生器和不间断电源，以及进入 包括液体闪烁计数器在内的共享仪器。 CPPF由药学和医学教授Jan Beumer博士和John Schmitz博士，医学副教授，由一个由以下组成的肝细胞癌咨询委员会监督 肝细胞癌成员。Beumer博士领导和Schmitz博士积极参与美林艾戈林周刊 翻译研究会议，在会上，肝癌早期药物开发项目由一个 由基础、翻译和临床科学家组成的学科小组，从而确保适当的考虑 CPPF在这些项目中的作用。 在这一供资期间，保护儿童基金会分析了总共36名独立调查人员的样本，并提供了 支持所有7个肝细胞癌研究项目。在这一资助期间，CPPF开发了37种新的检测方法，以及 平均每年使用22次化验，分析了30,000多个样品(不包括 校准器、质量控制或分析验证样品)。CPPF支持了30笔同行审查的赠款和70笔 出版物，其中30篇侧重于临床试验，19篇侧重于新药的开发 化验方法。